Titre :
  • Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Auteur : Galmarini, Carlos M ; Treilleux, I ; Cardoso, Fatima ; Bernard, Chantal ; Durbecq, Virginie ; Gancberg, David ; Bissery, Marie Christine ; Paesmans, Marianne ; Larsimont, Denis ; Piccart-Gebhart, Martine ; Di Leo, Angelo ; Dumontet, Charles
Informations sur la publication : Clinical cancer research, 14, 14, (page 4511-4516)
Statut de publication : Publié, 2008-07
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- metabolism
Doxorubicin -- therapeutic use
Drug Resistance, Neoplasm -- physiology
Female
Humans
Immunohistochemistry
Middle Aged
Protein Isoforms -- biosynthesis
Taxoids -- therapeutic use
Tubulin -- biosynthesis
Tumor Markers, Biological -- analysis
Note : Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langue :
  • Anglais
Identificateurs : urn:issn:1078-0432 
info:doi/10.1158/1078-0432.CCR-07-4741
info:pii/14/14/4511
info:pmid/18628466